# OnCo record nct04576455 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04576455/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04576455", "NCT04576455" ;
  schema:name "A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)"@en ;
  schema:description "A phase 2 trial of Giredestrant and Fulvestrant in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04576455/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04576455> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2020-11-27" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:drugs <https://onco.cc/drugs/giredestrant/>, <https://onco.cc/drugs/fulvestrant/> ;
  onco:companies <https://onco.cc/companies/flatiron-health/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04576455-j-clin-oncol-2024/> .